DSCSA and Diversion Prevention: How Track-and-Trac…

The Drug Supply Chain Security Act created a federal framework for tracing prescription drugs from manufacturer to dispenser. For diversion prevention programs, DSCSA is more than a supply-chain compliance obligation — it is a set of controls that helps confirm the integrity of every product arriving at your pharmacy before it ever reaches a patient.

What Is DSCSA?

The Drug Supply Chain Security Act (DSCSA) is Title II of the Drug Quality and Security Act, enacted by Congress in 2013. It establishes a national framework for tracking and tracing prescription drug products through the pharmaceutical supply chain — from manufacturer through wholesale distributors to dispensers, which include retail pharmacies, hospital pharmacies, and other health system dispensing sites.

The law's central goal is to protect patients from counterfeit, stolen, contaminated, or otherwise fraudulent drugs entering the supply chain. It does this by requiring every handoff of a prescription drug product between trading partners to be accompanied by verified electronic transaction data, and by mandating that any product with reason to question its legitimacy be quarantined and investigated before it is dispensed or sold.

DSCSA applies to all "prescription drug products" as defined under the Federal Food, Drug, and Cosmetic Act. The vast majority of controlled substances dispensed in pharmacies are prescription drug products and fall within DSCSA's scope. That makes the law directly relevant to pharmacy diversion compliance teams, not just supply-chain operations staff.

The Enforcement Timeline: November 2024 and May 2025

DSCSA's unit-level tracing requirements — the most operationally significant part of the law — had a long and phased implementation timeline. The statutory full enforcement date was November 27, 2024. By that date, trading partners were required to be exchanging complete electronic transaction data at the individual serialized package level and to be capable of verifying product against that data.

Following November 27, 2024, FDA provided an informal stabilization period to allow the industry to work through interoperability and system readiness challenges. That stabilization period ended May 27, 2025. Beginning on that date, FDA began enforcing the full requirements of DSCSA's enhanced drug distribution security provisions. Pharmacies and health systems that had been operating under the stabilization period's informal flexibility no longer had that buffer — full compliance is now expected and enforceable.

The practical implication: if your pharmacy or health system has not completed its DSCSA implementation — including electronic data receipt, product verification workflows, and suspect product procedures — that gap is now an active regulatory exposure, not a future problem.

Transaction Data: TI, TH, TS, and the T3 Requirement

At the core of DSCSA's tracing framework is a requirement that every sale or transfer of a prescription drug product between trading partners be accompanied by three categories of transaction data, collectively referred to as the "T3" data:

Transaction Information (TI): The product identifier (including NDC, serial number, lot number, and expiration date), the quantity, the date of the transaction, the business name and address of the entity transferring ownership, and the business name and address of the entity receiving the product.
Transaction History (TH): A complete history of all prior TI for the product, tracing back through the supply chain to the original manufacturer. For a pharmacy receiving product from a wholesaler, the TH documents the manufacturer-to-wholesaler leg as well as the wholesaler-to-pharmacy leg.
Transaction Statement (TS): A statement from the entity transferring the product, attesting that it is an authorized trading partner, that the product was received from an authorized trading partner, that the product was not knowingly introduced into the supply chain in a fraudulent manner, and that the T3 data being provided is complete and accurate.

Critically, the T3 data must now be exchanged electronically. Paper documents, PDFs emailed between trading partners, and manual spreadsheets are no longer acceptable methods for T3 data exchange. The law requires interoperable electronic exchange, and the standard for that exchange is EPCIS — the Electronic Product Code Information Services standard developed by GS1. EPCIS provides a structured data format that allows trading partners' systems to share and interpret transaction data consistently, regardless of which software platform each party uses.

For pharmacy dispensers, the practical requirement is that your pharmacy management system or a connected middleware platform must be capable of receiving EPCIS-formatted transaction data from your wholesale distributors and making that data accessible for product verification and audit purposes.

Package-Level Product Identifiers

DSCSA requires that prescription drug products carry a standardized product identifier at the package level. Each saleable unit must bear four data elements, typically encoded in a 2D barcode (GS1 DataMatrix) on the package:

The National Drug Code (NDC)
A unique serial number assigned to that individual package
The lot number
The expiration date

Together, these four elements create a globally unique identifier for each serialized unit. The serial number is what elevates DSCSA from lot-level tracking — where you know which lot a product came from but not which individual package — to unit-level tracing, where each package can be individually identified, tracked through the supply chain, and verified against the T3 data associated with it.

Pharmacies receiving product must be able to scan and capture these identifiers. Many dispensing systems now integrate barcode scanning that captures the product identifier at the point of receiving, linking each physical package to the electronic T3 records received from the wholesaler.

Authorized Trading Partners

DSCSA restricts transactions to "authorized trading partners." A manufacturer, wholesale distributor, or dispenser is an authorized trading partner only if it holds the appropriate license under state law and, where applicable, a federal registration. Wholesale distributors must also report certain information to FDA's drug distributor database. Trading partners are required to confirm that the entities they transact with are authorized before completing a purchase or sale.

For pharmacies, the authorized-trading-partner requirement means verifying that your wholesale distributors are properly licensed. This is typically confirmed by reviewing state wholesale distributor licenses and ensuring that your primary and secondary wholesalers maintain active, valid credentials. Purchasing product from an entity that is not an authorized trading partner — even inadvertently — is a DSCSA violation and raises immediate questions about the integrity of the product received.

Suspect Product: Quarantine and Verification

DSCSA creates explicit obligations when a pharmacy or other trading partner has reason to believe that a product may be suspect — meaning there is reason to question the product's legitimacy, such as an apparent discrepancy in the product identifier, damage or tampering evidence, an unexpected source, or a mismatch between the physical product and the accompanying T3 data.

When suspect product is identified, the product must be quarantined immediately — segregated from saleable product and not dispensed to patients. The pharmacy must then investigate, which at minimum means attempting to verify the product's authenticity against the manufacturer's or FDA's verification systems. If the product cannot be verified and the concern cannot be resolved, it must be treated as illegitimate product and handled accordingly under DSCSA's disposition requirements, which include notifying FDA and the immediate trading partner from whom the product was received.

DSCSA also requires that pharmacies verify the product identifier for product returned to the supply chain as saleable returns — that is, for product being returned to a wholesaler for credit and potential re-sale. A pharmacy cannot simply return product to the wholesaler without verifying that the product identifier is valid and matches the T3 records, because a fraudulent or tampered product re-entering the supply chain represents a direct patient safety risk.

The Diversion Connection: Supply-Chain Integrity and Controlled Substances

The overlap between DSCSA compliance and controlled substance diversion prevention is more direct than it might initially appear. Diversion does not occur only inside the four walls of a pharmacy — it also occurs at the supply-chain level, where counterfeit product containing diluted or substituted active ingredients can replace legitimate controlled substances, and where stolen product can be re-introduced into the supply chain through unauthorized distributors.

A pharmacy with strong DSCSA controls is a pharmacy that can confirm the integrity of every controlled substance received before it enters the dispensing inventory. When T3 data is received electronically and matched to incoming shipments, discrepancies surface immediately rather than months later during a DEA inspection. When suspect product is quarantined and investigated, a diluted or substituted controlled substance — which a diverter might use to mask a theft — has a much shorter dwell time in the pharmacy before it is identified.

Pharmacy diversion prevention programs should integrate DSCSA records into their compliance audit trail alongside controlled substance records. Specifically:

Confirm your trading partners are authorized. Every wholesale distributor supplying controlled substances to your facility should be verified as an authorized trading partner under DSCSA before the first purchase and periodically thereafter. An unauthorized distributor is not just a DSCSA violation — it is a serious indicator that the integrity of the controlled substances received from that source cannot be assured.
Verify incoming controlled substance shipments. Use your EPCIS-connected receiving workflow to match product identifiers on incoming controlled substance packages against the T3 data received from your wholesaler. Anomalies — missing serial numbers, mismatched lot or expiration data, packages not present in the T3 records — warrant immediate investigation before the product enters the dispensing inventory.
Treat suspect product procedures as a diversion control. When a controlled substance package triggers suspect-product review, apply the same documentation standards you would for a DEA-reportable discrepancy: record who identified the concern, the nature of the concern, what investigation was conducted, and the outcome. This record becomes part of your compliance file alongside your DEA 222 records, purchase invoices, and transaction logs.
Retain EPCIS records alongside controlled substance records. Just as DEA regulations require you to retain purchase records for two years, your DSCSA transaction data for controlled substance products should be retained and accessible for inspection. During a DEA diversion investigation, being able to produce a clean chain of custody from manufacturer to dispenser for a specific controlled substance lot strengthens your program's credibility.

DSCSA does not replace DEA recordkeeping requirements — both regulatory frameworks apply to controlled substance products simultaneously. The diversion prevention value of DSCSA is that it extends your visibility upstream, giving you tools to confirm that the controlled substances entering your inventory are legitimate before you account for them under DEA regulations.

DSCSA and Diversion Prevention: How Track-and-Trace Strengthens Your Program